HPR2 Baseline Characteristics of Patients Applying for Reimbursment of Liraglutide (Saxenda ®) for Weight Management Under a Managed Access Protocol in Ireland
To review baseline characteristics of applicants seeking reimbursement for liraglutide (Saxenda ®) for weight management, under a managed access protocol (MAP) operated by the Health Service Executive-Medicines Management Programme (HSE-MMP) in Ireland. In Phase I, Saxenda® is reimbursed for patients with a body mass index (BMI)>35kg/m2, with prediabetes and high-risk for cardiovascular disease.
Source: Value in Health - Category: International Medicine & Public Health Authors: C. Gorry, M. Daly, S. Doran, K. Finnigan, S. Clarke, M. Barry Source Type: research
More News: Cardiology | Cardiovascular | Heart | International Medicine & Public Health | Ireland Health | Victoza